(CLX)

Reporting relationship: Director
Issuer ticker: CLX
Reported as of: 31 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Apr 2026, 16:16:10 UTC
Prior SEC filing: 05 Feb 2026
Next SEC filing: 02 Apr 2026
Source filing: View source filing
Reporting owner signature: By Jinho Joo, Attorney-in-Fact

Key filing fact

Christopher J. Williams filed Form 4 for CLOROX CO /DE/ (CLX) on 02 Apr 2026.

Key facts

This page summarizes Christopher J. Williams's Form 4 filing for CLOROX CO /DE/ (CLX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 02 Apr 2026, 16:16.

Change

Previous filing in this sequence was filed on 05 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001269949 Primary reporting owner

WILLIAMS CHRISTOPHER J

Relationship: Director
Address: 1221 BROADWAY, OAKLAND
Signature: By Jinho Joo, Attorney-in-Fact
Signature date: 02 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLX transaction Derivative

Deferred Stock Units

Award

Transaction value
Shares: +213
Change %: +0.98%
Price: $0.000000^*
Shares after: 21,809
Date: 13 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 213
Exercise price
Footnotes: F1, F2, F3

CLX transaction Derivative

Deferred Stock Units

Award

Transaction value
Shares: +265
Change %: +1.2%
Price: $0.000000^*
Shares after: 22,075
Date: 31 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 265
Exercise price
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

1-for-1

Footnote F2

Deferred Stock Units acquired through dividend reinvestment during the fiscal year pursuant to the Independent Directors' Deferred Compensation Plan.

Footnote F3

The Deferred Stock Units will be settled 100% in Clorox stock in connection with the reporting person's retirement or other termination of service as a Director.

Footnote F4

Receipt of Deferred Stock Units in lieu of receipt of quarterly director's fees.